Shionogi has struck a deal to take…
Shionogi has struck a deal to take full control of [...]
Innovent Biologics’ eye disease…
Innovent Biologics’ eye disease prospect has matched Bayer and Regeneron’s [...]
Gilead increased CEO Daniel…
Gilead increased CEO Daniel O’Day’s compensation by 20% in 2025, [...]
Insmed has revealed results from a…
Insmed has revealed results from a trial of Arikayce, which [...]
A pair of rivals developing drugs…
A pair of rivals developing drugs for common retinal diseases [...]
Apogee Therapeutics has published…
Apogee Therapeutics has published phase 2 eczema data that suggest [...]
Sanofi has returned to T-cell…
Sanofi has returned to T-cell engager territory via an agreement [...]
Pfizer and Valneva have blamed…
Pfizer and Valneva have blamed “fewer than anticipated” Lyme disease [...]
Genentech is halting development…
Genentech is halting development of an antibody for two rare [...]
With patents expiring today in…
With patents expiring today in India for Novo Nordisk’s popular [...]